Highlights 2026 Milestones; Says Pivotal Phase 3 Trials In Wet AMD On Track For Data Readout Beginning In Mid-2026; Phase 3 DME Program First Patient Dosing Expected In Q1 2026

– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –

– Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 –

– Phase 3 DME program first patient dosing expected in Q1 2026 –

– Presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT –

WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today reported a corporate update and anticipated 2026 pivotal milestones for its lead product candidate, DURAVYU™ (vorolanib intravitreal insert).